TAFAMIDIS IN TRANSTHYRETIN AMYLOID CARDIOMYOPATHY

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive cardiac disease caused by accumulation of misfolded transthyretin (TTR) amyloid fibrils in the heart. TTR normally exists as a stable tetramer, but aging or disease-causing variants can reduce its stability. Dissociation of the tetramer into unstable monomers is an important step in amyloid formation. Tafamidis is a smallmolecule TTR kinetic stabilizer that binds to the thyroxine-binding sites of TTR and helps maintain the tetrameric structure. By reducing tetramer dissociation, tafamidis reduces the formation of new amyloid material. The clinical importance of tafamidis was demonstrated in the ATTR-ACT phase 3 trial. In 441 patients with ATTR-CM, tafamidis treatment was associated with lower all-cause mortality and cardiovascularrelated hospitalization compared with placebo over 30 months. Tafamidis also slowed deterioration in exercise capacity and health-related quality of life. Subsequent systematic reviews and meta-analyses have supported these findings. A 2023 meta-analysis involving 15 studies and 2765 patients found a lower risk of all-cause death or heart transplantation and a lower risk of composite adverse cardiovascular outcomes. A 2025 systematic review and meta-analysis also found lower mortality and fewer congestive heart failure exacerbations. More recent evidence has investigated cardiac imaging, biomarkers, myocardial strain and serial bone scintigraphy. A 2025 study reported reductions in cardiac [99mTc]Tc-DPD uptake after tafamidis treatment in patients with wild-type ATTR-CM. A 2026 systematic review reported potential stabilization of global longitudinal strain, preservation of functional status and lower all-cause mortality, although heterogeneity remained among studies. Overall, available evidence supports tafamidis as a disease-modifying treatment that slows the progression of ATTR-CM. Early diagnosis, appropriate patient selection, long-term treatment and further research into amyloid regression and disease monitoring remain important.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-13
DOI
https://doi.org/10.5281/zenodo.24189397
Primary Topic
Amyloidosis: Diagnosis, Treatment, Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

TAFAMIDIS IN TRANSTHYRETIN AMYLOID CARDIOMYOPATHY

Santosh Sarode, Manish Ahire, Pooja Gadhe, Piyush Sonawane et al.
1 links
Zenodo (CERN European Organization for Nuclear Research)
Amyloidosis: Diagnosis, Treatment, Outcomes
article

TAFAMIDIS IN TRANSTHYRETIN AMYLOID CARDIOMYOPATHY

Santosh Sarode, Manish Ahire, Pooja Gadhe, Piyush Sonawane, Ghule Ganesh, Pratik More, Chetan Salave
article en

Abstract

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive cardiac disease caused by accumulation of misfolded transthyretin (TTR) amyloid fibrils in the heart. TTR normally exists as a stable tetramer, but aging or disease-causing variants can reduce its stability. Dissociation of the tetramer into unstable monomers is an important step in amyloid formation. Tafamidis is a smallmolecule TTR kinetic stabilizer that binds to the thyroxine-binding sites of TTR and helps maintain the tetrameric structure. By reducing tetramer dissociation, tafamidis reduces the formation of new amyloid material. The clinical importance of tafamidis was demonstrated in the ATTR-ACT phase 3 trial. In 441 patients with ATTR-CM, tafamidis treatment was associated with lower all-cause mortality and cardiovascularrelated hospitalization compared with placebo over 30 months. Tafamidis also slowed deterioration in exercise capacity and health-related quality of life. Subsequent systematic reviews and meta-analyses have supported these findings. A 2023 meta-analysis involving 15 studies and 2765 patients found a lower risk of all-cause death or heart transplantation and a lower risk of composite adverse cardiovascular outcomes. A 2025 systematic review and meta-analysis also found lower mortality and fewer congestive heart failure exacerbations. More recent evidence has investigated cardiac imaging, biomarkers, myocardial strain and serial bone scintigraphy. A 2025 study reported reductions in cardiac [99mTc]Tc-DPD uptake after tafamidis treatment in patients with wild-type ATTR-CM. A 2026 systematic review reported potential stabilization of global longitudinal strain, preservation of functional status and lower all-cause mortality, although heterogeneity remained among studies. Overall, available evidence supports tafamidis as a disease-modifying treatment that slows the progression of ATTR-CM. Early diagnosis, appropriate patient selection, long-term treatment and further research into amyloid regression and disease monitoring remain important.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Amyloidosis: Diagnosis, Treatment, Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon